Inhibitory effects of flavonoids on glucose transporter 1 (GLUT1): From library screening to biological evaluation to

Yanhong Sun1, Xiaoyan Duan1, Fenghe Wang1

  • 1State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD study, Beijing Key Laboratory of Active Substances Discovery and Drug Ability Evaluation, Department of Drug Metabolism, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.

Toxicology
|March 4, 2023
PubMed

Insights

Certain flavonoids can inhibit glucose transporter 1 (GLUT1), a key factor in tumor growth. Sinensetin and nobiletin show promise in enhancing cancer drug sensitivity by targeting GLUT1.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Glucose transporter 1 (GLUT1) is crucial for tumor cell aerobic glycolysis and progression.
  • Inhibiting GLUT1 is a potential cancer therapy strategy, enhancing drug sensitivity.
  • Flavonoids, natural compounds, may inhibit GLUT1 and sensitize cancer cells to drugs like sorafenib.

Purpose of the Study:

  • Screen flavonoids as GLUT1 inhibitors.
  • Evaluate their potential to enhance sorafenib's efficacy in cancer cells.
  • Elucidate structure-activity relationships for flavonoid-GLUT1 interactions.

Main Methods:

  • Screened 98 flavonoids for GLUT1 inhibition in GLUT1-HEK293T cells.
  • Assessed sorafenib sensitization in HepG2 cells.
  • Utilized molecular docking and pharmacophore modeling.

Main Results:

  • Eight flavonoids, including sinensetin and nobiletin, significantly inhibited GLUT1 (>50%).
  • Sinensetin and nobiletin demonstrated potent sensitization effects, reducing HepG2 cell viability with sorafenib.
  • Molecular docking indicated hydrogen bonds, not Pi interactions, are key for inhibition.

Conclusions:

  • Sinensetin and nobiletin are promising sensitizers for enhancing sorafenib efficacy via GLUT1 inhibition.
  • Findings provide insights for designing novel GLUT1 inhibitors from flavonoids.
  • This approach may help overcome cancer drug resistance.

Related Concept Videos

Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
23.8K
Glucose Absorption Into the Small Intestine01:26

Glucose Absorption Into the Small Intestine

Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.9K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
228
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
224
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
830
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
202